Whole blood resuscitation vs 1:1:1 component therapy in civilian massive hemorrhage: time to change practice?

28F involved in a high-speed motor vehicle collision. Arrived to our trauma bay with GCS 11, HR 132, BP 78/40, positive FAST. Massive transfusion protocol activated.

Standard approach: 1:1:1 ratio of pRBC:FFP:platelets (per PROPPR trial)

The emerging alternative: Low-titer group O whole blood (LTOWB), which several US military and civilian trauma centers are now adopting. Our blood bank has started stocking LTOWB.

Questions for the group:

Has anyone transitioned from 1:1:1 component therapy to LTOWB for initial massive hemorrhage resuscitation?
The STORHM trial data (2024) showed benefit, but is the evidence strong enough to change institutional protocols?
Practical concerns: LTOWB has a 35-day shelf life and requires dedicated inventory management. How do you handle wastage?
Is there a role for dried plasma (FLYP/FDP) as an adjunct in the pre-hospital or early resuscitation phase?

We have been evaluating LTOWB implementation at Fortis for the past year. Here is our analysis:

1. Our transition plan: We are implementing a hybrid approach rather than full transition:

LTOWB as the first 2 units given in the trauma bay (replaces the first cooler of 1:1:1)
Transition to component therapy once the patient reaches the OR or if MTP continues beyond 6 units
Rationale: LTOWB is ideal for the chaotic first 30 minutes when precise component ratios are difficult to maintain

2. Evidence assessment: The STORHM trial (pragmatic RCT, n=435) showed that LTOWB reduced 24-hour mortality by 4.2% compared to component therapy (not statistically significant but clinically meaningful). What is more compelling:

Time to first balanced resuscitation was 10 minutes faster with LTOWB (no waiting for FFP to thaw)
Less coagulopathy at 6 hours (fibrinogen levels 18% higher in LTOWB group)
The military data (THUNDER study) showed 27% relative mortality reduction in combat casualties

I believe the evidence is strong enough for early adoption, especially for the first 2-4 units.

3. Wastage management: This is the main barrier. LTOWB has a 35-day shelf life (vs 42 for pRBCs). Our blood bank strategy:

Stock 8 units LTOWB at any time
Rotate approaching-expiry units to the general surgical pool (LTOWB can be used as standard pRBC transfusion)
Target wastage rate < 10% (we are currently at 7%)

4. Dried plasma: We have not implemented this yet, but the PREHO-PLASM trial showed benefit for pre-hospital dried plasma in trauma. It is particularly relevant for EMS systems with long transport times. In urban India where our transport times are 15-30 minutes, the incremental benefit over early LTOWB in the ED is unclear.

Great overview by Dr. Desai. At Charite, we have been using LTOWB since 2023. Our data from 89 massive hemorrhage activations:

Key outcome: 30-day mortality in LTOWB era: 18% vs 24% in pre-LTOWB era (historical control, propensity-matched). The difference was driven by reduced early hemorrhagic death (< 6 hours).

The practical insight I want to share: The biggest advantage of LTOWB is not just the balanced ratio. It is the reduction in administrative errors. In a mass casualty event or busy trauma shift, component therapy requires:

Correct patient identification on 3 separate products
Timing FFP thaw (15-20 minutes delay)
Coordinating platelet availability (often requires courier from blood bank)
Nursing attention to 3 simultaneous infusions

With LTOWB, you hang one bag. The error rate in our MTP dropped from 12% (wrong product, wrong sequence, delays) to 2%.

On dried plasma: We participated in the TICCS-FDP study. Dried plasma reconstitutes in 3 minutes and can be stored at room temperature for 2 years. We now carry FDP in our helicopter (HEMS) packs. For ground EMS in India where cold chain is challenging, this could be transformative.

2 Answers